Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β-blockers in SURVIVE†

Por Mebazaa, Alexandre, Nieminen, Markku S., Filippatos, Gerasimos S., Cleland, John G., Salon, Jeffrey E., Thakkar, Roopal, Padley, Robert J., Huang, Bidan, Cohen-Solal, Alain
Publicado em 2009

Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial

Por Inoue, Nagamu, Kobayashi, Kiyonori, Naganuma, Makoto, Hirai, Fumihito, Ozawa, Morio, Arikan, Dilek, Huang, Bidan, Robinson, Anne M., Thakkar, Roopal B., Hibi, Toshifumi
Publicado no Intest Res (2017)

Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies

Por Louis, Edouard J., Reinisch, Walter, Schwartz, David A., Löfberg, Robert, Robinson, Anne M., Berg, Sofie, Wang, Anthony W., Maa, Jen-fue, Huang, Bidan, Pappalardo, Brandee
Publicado no Adv Ther (2018)

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Por Suzuki, Yasuo, Motoya, Satoshi, Hanai, Hiroyuki, Hibi, Toshifumi, Nakamura, Shiro, Lazar, Andreas, Robinson, Anne Martin, Skup, Martha, Mostafa, Nael Mohamed, Huang, Bidan, Thakkar, Roopal, Watanabe, Mamoru
Publicado no J Gastroenterol (2017)

Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Por Suzuki, Yasuo, Motoya, Satoshi, Hanai, Hiroyuki, Hibi, Toshifumi, Nakamura, Shiro, Lazar, Andreas, Robinson, Anne Martin, Skup, Martha, Mostafa, Nael Mohamed, Huang, Bidan, Thakkar, Roopal, Watanabe, Mamoru
Publicado no J Gastroenterol (2017)

Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease

Por Dubinsky, Marla C., Rosh, Joel, Faubion, William A., Kierkus, Jaroslaw, Ruemmele, Frank, Hyams, Jeffrey S., Eichner, Samantha, Li, Yao, Huang, Bidan, Mostafa, Nael M., Lazar, Andreas, Thakkar, Roopal B.
Publicado no Inflamm Bowel Dis (2016)

Briakinumab for Treatment of Crohn's Disease: Results of a Randomized Trial

Por Panaccione, Remo, Sandborn, William J., Gordon, Glenn L., Lee, Scott D., Safdi, Alan, Sedghi, Shahriar, Feagan, Brian G., Hanauer, Stephen, Reinisch, Walter, Valentine, John F., Huang, Bidan, Carcereri, Roberto
Publicado no Inflamm Bowel Dis (2015)

Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn’s disease: results from a randomized trial

Por Chen, Baili, Gao, Xiang, Zhong, Jie, Ren, Jianlin, Zhu, Xuan, Liu, Zhanju, Wu, Kaichun, Kalabic, Jasmina, Yu, Zhuqing, Huang, Bidan, Kwatra, Nisha, Doan, Thao, Robinson, Anne M., Chen, Min-Hu
Publicado no Therap Adv Gastroenterol (2020)

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3

Por Colombel, Jean-Frederic, Sandborn, William J, Ghosh, Subrata, Wolf, Douglas C, Panaccione, Remo, Feagan, Brian, Reinisch, Walter, Robinson, Anne M, Lazar, Andreas, Kron, Martina, Huang, Bidan, Skup, Martha, Thakkar, Roopal B
Publicado no Am J Gastroenterol (2014)